Sugi Predict

Sugi Predict / Compounds / SCHEMBL2974808

SCHEMBL2974808

SCHEMBL2974808

COc1ccccc1S(=O)(=O)N(C)c1cccc2cc(C3=NCC(CC(N)=O)S3)[nH]c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ MAPT P10636 4/20 0.33
▸ LMNA P02545 3/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ DAGLA Q9Y4D2 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ KLK7 P49862 1/20 0.32
▸ HPGD P15428 3/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ ITK Q08881 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ MTOR P42345 2/20 0.31
▸ RICTOR Q6R327 2/20 0.31
▸ RPTOR Q8N122 2/20 0.31
▸ MAPKAP1 Q9BPZ7 2/20 0.31
▸ MLST8 Q9BVC4 2/20 0.31
▸ RIPK2 O43353 1/20 0.31
▸ RET P07949 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2668856 0.93 DAGLA (0.36) POLBALDH1A1HSD17B10MAPTLMNA
SCHEMBL2972268 0.91 ALDH1A1 (0.33) POLBALDH1A1HSD17B10MAPTLMNA
SCHEMBL2668834 0.91 HPGD (0.33) POLBALDH1A1HSD17B10MAPTLMNA
SCHEMBL13204178 0.90 ALDH1A1 (0.35) POLBALDH1A1HSD17B10MAPTLMNA
SCHEMBL13221872 0.89 MAPT (0.35) POLBALDH1A1HSD17B10MAPTLMNA
SCHEMBL13222222 0.89 ITK (0.34) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL2668850 0.89 LMNA (0.34) POLBALDH1A1HSD17B10MAPTLMNA
SCHEMBL2971591 0.86 ALDH1A1 (0.34) POLBALDH1A1MAPTLMNAMAPK1
SCHEMBL2668643 0.85 SLC40A1 (0.42) POLBALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2966565 0.85 LMNA (0.32) POLBALDH1A1MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410087-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-02 — — US disclosed
US-8410087-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-02 — — US disclosed
US-8410087-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-02 — — US disclosed
EP-2508524-A2 Indole compound Takeda Pharmaceutical Company Limited (JP) 2012-10-10 — — EP disclosed
US-7777047-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-17 — — US disclosed
US-7777047-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-17 — — US disclosed
US-20100144702-A1 INDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-10 — — US disclosed
US-20100144702-A1 INDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-10 — — US disclosed
US-20100137610-A1 Indole compound YASUMA TSUNEO 2010-06-03 — — US disclosed
US-20100137610-A1 Indole compound YASUMA TSUNEO 2010-06-03 — — US disclosed
US-7718798-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-18 — — US disclosed
US-7718798-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-18 — — US disclosed
US-7652133-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-26 — — US disclosed
US-7652133-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-26 — — US disclosed
US-20090286975-A1 Indole compound YASUMA TSUNEO 2009-11-19 — — US disclosed
US-20090286975-A1 Indole compound YASUMA TSUNEO 2009-11-19 — — US disclosed
US-20080096877-A1 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-04-24 — — US disclosed
US-20080096877-A1 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144702-A1 INDOLE COMPOUND GCKR, GPR119, SLC5A1 POLB 4570/4885ALDH1A1 376/4885HSD17B10 579/4885
US-20100137610-A1 Indole compound GCKR, GPR119, SLC5A1 POLB 4570/4885ALDH1A1 376/4885HSD17B10 579/4885
US-20090286975-A1 Indole compound GCKR, GPR119, SLC5A1 POLB 4570/4885ALDH1A1 376/4885HSD17B10 579/4885
US-20080096877-A1 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example GCKR, GCK, KHK POLB 4403/4885ALDH1A1 296/4885HSD17B10 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.